Tourette Syndrome has Substantial Impact in Childhood and Adulthood As Well

*Department of Neurology, University of Florida Movement Disorders Center, Gainsville, FL; †Tourette Association of America, Bayside, NY; ‡Department of Psychology, The University of Utah, Salt Lake City, UT. Address for reprints: Diana Shineman, PhD, Tourette Association of America, 42-40 Bell Boulevard, Ste 205, Bayside, NY 11361; e-mail: [email protected]. The 2018 TAA Impact Survey was supported and conducted by the Tourette Association of America Disclosure: I. Malaty has been PI of a Tourette Association of America (TAA) center of excellence and has received travel compensation and honoraria for speaking for the TAA. Unrelated to the content of this article, I. Malaty has participated in research funded by the Parkinson Foundation, Tourette Association, Dystonia Coalition, Abbvie, Auspex, Biogen, Biotie, Intrepid, Lily, Lundbeck, Neurocrine, Pfizer, Revance, and Teva but has no owner interest in any pharmaceutical company. She has received travel compensation from the NeuroChallenge Foundation and NIH/Neurobiology of Disease in Children conference, honoraria from Medscape (12/18) and Cleveland Clinic (1/19), and royalties for writing a Parkinson book with Robert Rose publishers. Michael Himle has received research funding from the National Institutes of Health and the Tourette Association of America (TAA). He is a member of the TAA Medical Advisory Board and receives speaking honoraria from the TAA for talks on various topics related to Tourette Syndrome. See related article on page 407.